# Pfizer Inc. (PFE)

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-12  
**Report type:** Primer (steps 1–3 of 19)  
**API endpoint:** GET /api/v1/research/PFE/primer

## Business Model

---
ticker: PFE
step: 01
generated: 2026-05-12
source: quick-research
---

### Pfizer Inc. (PFE) — Business Overview

#### Business Description
Pfizer is one of the world's largest research-based biopharmaceutical companies, operating in 125+ countries with significant sales in North America, Europe, and emerging markets. The company is in the middle of a multi-year strategic pivot — diversifying away from COVID-era windfalls and toward a portfolio anchored by oncology (post-Seagen), vaccines, rare diseases, and a newly aggressive obesity push (Metsera acquisition). Six priority therapeutic areas: Oncology, Vaccines, Inflammation & Immunology, Rare Diseases, Internal Medicine, and Anti-Infectives.

#### Revenue Model
- **Branded pharmaceutical sales (~98% of revenue):** Direct sales to pharmacies, hospitals, payers, and PBMs in the US plus international markets (mostly via subsidiaries). Pricing is list-minus-rebate in the US, with materially lower realized prices ex-US.
- **Vaccines:** Prevnar 20 (pneumococcal), COVID products (Comirnaty + Paxlovid — declining), Abrysvo (RSV), routine immunization franchises (e.g., Trumenba).
- **Oncology (28% of revenue, growing fast):** Ibrance, Xtandi (partnered with Astellas), Lorbrena, Braftovi/Mektovi, plus the four marketed Seagen ADCs — ADCETRIS, PADCEV, TIVDAK, TUKYSA. Combined oncology contributed $3.4B from Seagen products in FY2024.
- **Internal Medicine:** Eliquis (with BMS), Vyndaqel family (transthyretin amyloidosis), Pristiq, Lyrica generics.
- **Specialty / Inflammation & Immunology:** Xeljanz, Cibinqo, Litfulo.
- **Royalties & collaborations:** Income from partnerships including BMS on Eliquis, Astellas on Xtandi.

The strategic narrative is shifting from blockbuster small-molecule primary care toward higher-margin, longer-duration oncology biologics and ADCs.

#### Products & Services
**Vaccines:**
- Comirnaty (COVID-19 mRNA, with BioNTech)
- Prevnar 20 (pneumococcal)
- Abrysvo (RSV for older adults and maternal)
- Trumenba (meningitis B)

**Oncology:**
- Ibrance (palbociclib) — CDK4/6 inhibitor
- Xtandi (enzalutamide) — prostate cancer
- Vyndaqel / Vyndamax (tafamidis) — ATTR-CM
- Lorbrena (lorlatinib) — NSCLC
- ADCETRIS, PADCEV, TIVDAK, TUKYSA (Seagen ADCs)
- Talzenna, Braftovi/Mektovi, Bavencio (with Merck KGaA)

**Internal Medicine / Cardiometabolic:**
- Eliquis (apixaban, with BMS)
- Vyndaqel family
- Metsera obesity portfolio (post $10B acquisition)

**Inflammation & Immunology:**
- Xeljanz, Cibinqo, Litfulo, Inflectra

**Rare Disease / Hematology:**
- BENEFIX, REFACTO AF, Beqvez (gene therapy)

**Anti-Infectives:**
- Paxlovid (COVID antiviral, declining)
- Zithromax, antibacterials

**Pipeline (April 2025):** 108 total candidates — 47 Phase 1, 28 Phase 2, 30 Phase 3, 3 pending approval.

#### Customer Base & Go-to-Market
- **US (~50% of revenue):** Sold through PBMs, retail pharmacies, hospitals, specialty distributors; significant DTC marketing for Eliquis, Vyndaqel family, Abrysvo.
- **International (~50%):** Direct sales subsidiaries in 100+ countries; Europe, Japan, China are largest markets. Emerging markets growing as middle-class healthcare access expands.
- **Hospital & specialty channels:** Heavily weighted for oncology and rare disease franchises.
- **Government / public health:** Vaccines (Prevnar, RSV, COVID) — payer mix includes Medicare Part B/D, CDC, GAVI, Ministry-level contracts globally.

No single customer represents material concentration. Geographic diversification is one of Pfizer's structural strengths.

#### Competitive Position
Pfizer is one of the top 5 global pharmaceutical companies by revenue (~$63B FY2024) and a top-tier presence in vaccines, oncology, and cardiometabolic. Key strengths: (1) **Seagen ADC platform** — the $43B Seagen acquisition (Dec 2023) gave Pfizer industry-leading ADC technology in target-selection, linkers, payloads, and manufacturing; oncology pipeline targeting $10B+ revenue by 2030, (2) **Vyndaqel franchise** — sole leader in ATTR amyloidosis indication with multi-year growth runway, (3) **Vaccine R&D + manufacturing** — Comirnaty mRNA platform plus traditional vaccine production capacity, (4) **Metsera obesity entry** — acquired for $10B after a public bidding war with Novo Nordisk, providing pipeline entry into GLP-1 / cardiometabolic alongside Lilly and Novo, (5) **Cost reset** — $7.7B cost reduction program by 2027 (with $500M reinvested into R&D productivity). Key weaknesses: $15–18B annual revenue loss from 2026–2028 patent cliffs (Eliquis, Ibrance, Xtandi, Prevnar 13), stretched balance sheet from Seagen + Metsera M&A, and underperformance vs. Lilly / Novo in obesity through 2025.

#### Key Facts
- Founded: 1849
- Headquarters: New York, NY
- Employees: ~88,000
- Exchange: NYSE
- Sector / Industry: Health Care / Pharmaceuticals
- Market Cap: ~$146B (May 2026)
- Dividend yield: ~6% — one of the highest in big pharma

## Financial Snapshot

---
ticker: PFE
step: 04
generated: 2026-05-12
source: quick-research
---

### Pfizer Inc. (PFE) — Financial Snapshot

#### Income Statement Summary

| Metric | FY2023 | FY2024 | FY2025 | YoY |
|--------|--------|--------|--------|-----|
| Revenue | $58.5B | $63.6B | $62.6B | -2% |
| Revenue ex-COVID (operational) | n/a | +12% | +6% | normalizing |
| Adj. Gross Margin | 71% | 74% | 75% | +1pp |
| Adj. Operating Margin | 21% | 26% | 27% | +1pp |
| Adj. Net Income | $6.8B | $11.0B | $11.5B | +5% |
| Adj. EPS | $1.84 | $3.11 | $3.20 | +3% |
| Free Cash Flow | $4.7B | $11.0B | $10.5B | -5% |

#### Top Products (FY2024)

| Product | FY2024 Sales | YoY |
|---------|--------------|-----|
| Eliquis | $7.3B | +9% (but IRA 2026) |
| Prevnar 20 | $6.4B | +5% |
| Vyndaqel/Vyndamax | $5.4B | +60%+ |
| Ibrance | $4.3B | -5% (CDK4/6 competition) |
| Comirnaty (COVID) | $5.4B | declining |
| Paxlovid | $5.7B | declining |
| Xtandi | $5.5B | +12% |
| Padcev (Seagen) | growing | first-line bladder |

#### 2026 Guidance

| Metric | 2026 Guide |
|--------|------------|
| Revenue | $59.5-62.5B |
| IRA Eliquis Impact | -$1B (-1.6% drag) |
| LOE Headwind (cumulative 2025-2027) | $1.5B 2025 → $4.5B 2027 |

#### Patent Cliff Detail

| Year | LOE Impact |
|------|-----------|
| 2025 | $1.5B headwind |
| 2026 | Cumulative growing |
| 2027 | $4.5B annual headwind |
| 2028 | MET097 obesity launch (potential offset) |

#### Cash Flow & Balance Sheet (FY2025)

| Metric | Value |
|--------|-------|
| Operating Cash Flow | ~$12.5B |
| Capital Expenditures | ~$2.0B |
| Free Cash Flow | $10.5B |
| Cash & Investments | ~$11B |
| Total Debt | ~$60B (post-Seagen) |
| Net Debt/EBITDA | ~2.7x |

#### Key Ratios (approximate, May 2026)
- P/E (forward): ~10x | EV/EBITDA: ~9x | Dividend Yield: ~6.3%
- ROIC: ~9% (pre-Metsera)
- FCF Yield: ~7%

#### Growth Profile
FY25 revenue $62.6B (-2%) — COVID franchise headwind continues. Ex-COVID operational +6%. Eliquis +9% in 2024 but facing IRA Medicare negotiated price in 2026 = -$1B headwind. Seagen integration progressing. Patent cliff: $21.4B of 2024 revenue at risk through 2028. Obesity gap until MET097 in 2028. Pfizer reaffirmed 2026 guidance of $59.5-62.5B.

#### Forward Estimates
- **FY2026E Revenue:** $59.5-62.5B (mgmt guide; flat to -3%)
- **FY2026E Adj EPS:** ~$3.20-3.30
- **FY2027E EPS:** ~$3.00 (LOE peak headwind)
- **FY2028E EPS:** ~$3.50+ (MET097 launch potential)
- **2030+ Obesity Revenue (bull case):** $5-10B+

#### Capital Return
- Dividend $1.72 annual (~$9.7B paid) — 6.3% yield
- 15+ consecutive years of dividend growth
- Buybacks suspended for Seagen deleveraging
- Dividend coverage tight but management committed

## Recent Catalysts

---
ticker: PFE
step: 12
generated: 2026-05-12
source: quick-research
---

### Pfizer Inc. (PFE) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Seagen ADC integration + Padcev first-line bladder** — $43B Seagen acquisition integrated. Padcev + Keytruda combination is now first-line standard of care in bladder cancer. Multiple ADC pipeline candidates emerging from Seagen platform. Pfizer dedicating >40% R&D spend to oncology. ADCs represent the highest-growth oncology modality (alongside cell therapy).

2. **Obesity entry via Metsera + 10 Phase III MET097 trials** — $10B Metsera acquisition + YP05002 in-licensing. 10 Phase III trials starting on MET097 (ultra-long-acting GLP-1). Launch target 2028. Global obesity market ~$150B by 2030. While Pfizer is 3+ years behind Lilly/Novo, capturing even 10% of the obesity market = $15B annual revenue.

3. **6.3% dividend yield + cost discipline** — Highest dividend yield among large-cap pharma at 6.3%. Adj operating margin expanded 21% (FY23) → 27% (FY25) through cost reductions. Combined with 15+ consecutive years of dividend growth, PFE offers high-yield defensive profile if the patent cliff is navigated.

4. **Bourla leadership refresh signals R&D rebuild** — In 2025 Bourla elevated Chris Boshoff to CSO + brought in Jeff Legos from Novartis as CRO to fix R&D engine + Seagen integration. Aggressive cost program targeting $4B+ annual savings to fund pipeline.

#### Bear Case Risks

1. **Patent cliff is largest in industry — $21.4B at risk through 2028** — Pfizer's products with patent losses 2026-2027 generated $21.4B in 2024 (~1/3 of revenue). LOE headwind growing from $1.5B (2025) → $4.5B (2027). Ibrance LOE 2027, Eliquis IRA pressure 2026, Vyndaqel LOE 2028. No obesity launch until 2028.

2. **Eliquis IRA Medicare price negotiation — $1B 2026 hit** — Eliquis is #1 product subject to Medicare price negotiation. New price effective Jan 2026 cuts $1B from revenue (-1.6% growth headwind). This is a structural reset — future Eliquis revenue will be permanently lower than pre-IRA trajectory.

3. **Obesity gap until 2028 = 2-year vulnerability** — MET097 not launching before 2028 = 2-year window of Lilly Mounjaro/Zepbound + Novo Wegovy expanding market share. By 2028, oral GLP-1s (Lilly orforglipron) will be commercial. Pfizer entering obesity late + with a 2nd-generation product = uphill battle. Danuglipron failure (discontinued 2025) erased early momentum.

4. **TrumpRx pricing + acquisition track record** — "TrumpRx" environment in 2026 limits ability to take annual price hikes. Bourla's M&A track record questioned — bears note prior large deals (Warner-Lambert, Wyeth, Allergan, Hospira) had mixed returns. Investors skeptical that "buy our way out of patent cliff" works.

#### Upcoming Events

- **Q2 2026 earnings (July 2026)** — Eliquis post-IRA negotiated price trajectory; LOE drug performance
- **Q3 2026 earnings (October 2026)** — Mid-year reconfirmation of guidance
- **MET097 first Phase III readouts** — Late 2026 / 2027 — critical for obesity timeline
- **Comirnaty fall 2026 vaccination season** — Continued normalization
- **Padcev label expansion data**

#### Analyst Sentiment

Sell-side consensus is **Hold / Moderate Buy** with average price targets in the $30-32 range vs. recent ~$27 trading levels (~11-19% upside). Bulls cite 6.3% dividend yield, Seagen oncology integration, and Metsera optionality. Bears focus on patent cliff, Eliquis IRA reset, and 3-year obesity gap. Pfizer is a value name with binary obesity catalyst — most analysts see "wait and see" until MET097 Phase III data.

#### Research Date
Generated: 2026-05-12

## Full Research Available

This primer covers steps 1–3 of 19. The full deep dive (moat analysis, DCF, bull/bear,
management quality, earnings transcript analysis) is available via:

- Investment memo: /memo/pfe
- Full research API: GET /api/v1/research/PFE/memo
- Coverage universe: /stocks